Unlock the Power of Artificial Intelligence in Novel Drug Discovery

January 12, 2023
8:00 a.m. PST / 11:00 a.m. EST / 16:00 GMT / 17:00 CET - Duration: 60 Minutes


Discovering new “drug-like” and synthetically viable compounds via artificial intelligence (AI) is of great interest to medicinal chemists.  

One of the key challenges in using AI for drug discovery is the lack of robust machine learning (ML) models trained on experimentally proven data.    

In this webinar, learn how experimentally validated AI/ML methods and computational tools of the AIDDISON™ integrated platform can solve the challenges in drug design for medicinal chemists. 

Key Learning Objectives:
  • Unlock ingenuity for new molecule design tailored to your needs with AI methods and computational tools
  • Explore how AIDDISON can accelerate the process of hit identification and lead optimization
  • Discover AIDDISON’s generative methods for designing novel “drug-like” and synthetically viable compounds
  • Exploit machine learning toxicology models to guide pharmacokinetic profile search in ultra-large chemical spaces
Who Should Attend:
  • Medicinal Chemists
  • IT/Computational Chemists
  • Discovery Scientists
  • R&D Scientists
  • Group/Team Leaders
  • Director/VP-Level Executives
  • Data Scientists
  • Chief Scientific Officers

Brought to you by:
MilliporeSigma Logo


Ashwini Ghogare
Head of AI and Automation for Drug Discovery,
Global Science and Technology Group at Merck KGaA
Melissa O'Meara
Forensic Science Consultant,
C&EN Media Group


*By submitting this form, you agree to receive more information on related products and services from the American Chemical Society (ACS Publications) and its sponsor via email. ACS takes your privacy seriously. For more information, please see the ACS Privacy Policy.

© 2023 American Chemical Society, 1155 16th St NW, Washington, DC 20036, USA. View our Privacy Policy